JP2021531314A5 - - Google Patents
Info
- Publication number
- JP2021531314A5 JP2021531314A5 JP2021504283A JP2021504283A JP2021531314A5 JP 2021531314 A5 JP2021531314 A5 JP 2021531314A5 JP 2021504283 A JP2021504283 A JP 2021504283A JP 2021504283 A JP2021504283 A JP 2021504283A JP 2021531314 A5 JP2021531314 A5 JP 2021531314A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- alkyl
- group
- pharmaceutically acceptable
- solvate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862711273P | 2018-07-27 | 2018-07-27 | |
| US62/711,273 | 2018-07-27 | ||
| PCT/US2019/043608 WO2020023846A1 (en) | 2018-07-27 | 2019-07-26 | Pyridone a2r antagonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021531314A JP2021531314A (ja) | 2021-11-18 |
| JP2021531314A5 true JP2021531314A5 (enExample) | 2022-08-01 |
| JP7394831B2 JP7394831B2 (ja) | 2023-12-08 |
Family
ID=69182367
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021504283A Active JP7394831B2 (ja) | 2018-07-27 | 2019-07-26 | ピリドンａ２ｒアンタゴニスト |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US12064433B2 (enExample) |
| EP (1) | EP3829581B1 (enExample) |
| JP (1) | JP7394831B2 (enExample) |
| KR (1) | KR102809468B1 (enExample) |
| CN (1) | CN112996509B (enExample) |
| AU (1) | AU2019312296B2 (enExample) |
| CA (1) | CA3107079A1 (enExample) |
| ES (1) | ES2982326T3 (enExample) |
| PL (1) | PL3829581T3 (enExample) |
| WO (1) | WO2020023846A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES3070946T3 (en) | 2019-03-12 | 2026-06-18 | Arcus Biosciences Inc | Treatment of an oncogenene driven cancer having a kras or egfr mutation by decreasing adenosine production or antagonizing adenosine activation |
| CA3135487A1 (en) | 2019-03-29 | 2020-10-08 | Arcus Biosciences, Inc. | Treatment of cancer utilizing an identified adenosine fingerprint |
| CA3173831A1 (en) | 2020-03-19 | 2021-09-23 | Arcus Biosciences, Inc. | Tetralin and tetrahydroquinoline compounds as inhibitors of hif-2alpha |
| JP2021183587A (ja) * | 2020-05-22 | 2021-12-02 | 武田薬品工業株式会社 | 複素環化合物 |
| CA3179320A1 (en) | 2020-06-17 | 2021-12-23 | Arcus Biosciences, Inc. | Crystalline forms of a cd73 inhibitor and uses thereof |
| US11873291B2 (en) * | 2020-09-03 | 2024-01-16 | Immunesensor Therapeutics, Inc. | Quinoline cGAS antagonist compounds |
| KR20230153387A (ko) | 2021-02-02 | 2023-11-06 | 리미널 바이오사이언시스 리미티드 | Gpr84 길항제 및 이의 용도 |
| JP2024506858A (ja) | 2021-02-02 | 2024-02-15 | リミナル・バイオサイエンシーズ・リミテッド | Ｇｐｒ８４アンタゴニストおよびその使用 |
| KR20230158044A (ko) | 2021-03-18 | 2023-11-17 | 남미 테라퓨틱스, 인크. | 암의 치료에 유용한 A2aR 길항제 전구약물을 함유하는 제제화된 및/또는 공동-제제화된 리포솜 조성물 및 그의 방법 |
| EP4341262A1 (en) | 2021-05-21 | 2024-03-27 | Arcus Biosciences, Inc. | Axl inhibitor compounds |
| WO2022246177A1 (en) | 2021-05-21 | 2022-11-24 | Arcus Biosciences, Inc. | Axl compounds |
| TW202325279A (zh) | 2021-10-29 | 2023-07-01 | 美商阿克思生物科學有限公司 | HIF-2α抑制劑及其使用方法 |
| EP4486734A1 (en) | 2022-03-02 | 2025-01-08 | Immunesensor Therapeutics, Inc. | Quinoline cgas antagonist compounds |
| CN119156228A (zh) | 2022-05-02 | 2024-12-17 | 艾库斯生物科学有限公司 | 抗tigit抗体及其用途 |
| EP4554680A1 (en) | 2022-07-15 | 2025-05-21 | Arcus Biosciences, Inc. | Inhibitors of hpk1 and methods of use thereof |
| WO2024020034A1 (en) | 2022-07-20 | 2024-01-25 | Arcus Biosciences, Inc. | Cbl-b inhibitors and methods of use thereof |
| EP4602041A1 (en) | 2022-10-14 | 2025-08-20 | Arcus Biosciences, Inc. | Hpk1 inhibitors and methods of use thereof |
| CN120091809A (zh) | 2022-10-20 | 2025-06-03 | 艾库斯生物科学有限公司 | Cd73化合物的冻干制剂 |
| WO2024097736A1 (en) | 2022-11-02 | 2024-05-10 | Arcus Biosciences, Inc. | Processes for preparing azolopyrimidine compounds |
| EP4705292A1 (en) | 2023-05-05 | 2026-03-11 | Arcus Biosciences, Inc. | Cbl-b inhibitors and methods of use thereof |
| WO2024243502A1 (en) | 2023-05-25 | 2024-11-28 | Arcus Biosciences, Inc. | Cbl-b inhibitors and methods of use thereof |
| WO2025054339A1 (en) | 2023-09-08 | 2025-03-13 | Arcus Biosciences, Inc. | Triazolopyridine compounds as inhibitors of kit |
| WO2025072330A1 (en) | 2023-09-26 | 2025-04-03 | Arcus Biosciences, Inc. | Kit inhibitor compounds and methods of use thereof |
| EP4788432A1 (en) | 2023-10-06 | 2026-08-12 | Arcus Biosciences, Inc. | Cbl-b inhibitors and methods of use thereof |
| US12384773B2 (en) | 2023-11-02 | 2025-08-12 | Arcus Biosciences, Inc. | Thiazole compounds and methods of use thereof |
| WO2026006759A1 (en) | 2024-06-28 | 2026-01-02 | Arcus Biosciences, Inc. | Pharmaceutical compositions, dosage forms, and methods of making and using same |
| WO2026064493A1 (en) * | 2024-09-20 | 2026-03-26 | University Of South Florida | Inhibition of farnesyltransferase to treat cardiomyopathy and heart failure |
| AU2025271396B2 (en) * | 2024-10-30 | 2026-06-18 | Hanmi Pharm. Co., Ltd. | Novel heterobicyclic compound for inhibiting yap-tead interaction and pharmaceutical composition comprising same |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1615931A1 (en) | 2003-04-09 | 2006-01-18 | Biogen Idec MA Inc. | Triazolopyrazines and methods of making and using the same |
| TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| WO2006091898A2 (en) | 2005-02-25 | 2006-08-31 | Adenosine Therapeutics, Llc | Pyrazolyl substituted xanthines |
| JP5238936B2 (ja) | 2005-03-25 | 2013-07-17 | ジーアイティーアール，インク． | Ｇｉｔｒ結合分子およびその使用 |
| CA2646333C (en) * | 2006-03-17 | 2014-06-17 | Cv Therapeutics, Inc. | Method of preventing and treating hepatic disease using a2b adenosine receptor antagonists |
| WO2008156580A1 (en) * | 2007-06-13 | 2008-12-24 | Merck & Co., Inc. | Triazole derivatives for treating alzheimer's disease and related conditions |
| PT2175884T (pt) | 2007-07-12 | 2016-09-21 | Gitr Inc | Terapias de combinação empregando moléculas de ligação a gitr |
| IN2015DN02826A (enExample) | 2009-09-03 | 2015-09-11 | Merck Sharp & Dohme | |
| DK2542256T3 (da) | 2010-03-04 | 2019-08-26 | Macrogenics Inc | Antistoffer reagerende med b7-h3, immunologisk aktive fragmenter deraf og anvendelser deraf |
| NZ729044A (en) | 2010-09-09 | 2020-07-31 | Pfizer | 4-1bb binding molecules |
| DK2820006T3 (da) * | 2012-02-29 | 2017-11-06 | Chemocentryx Inc | Pyrazol-1-yl benzen sulfonamider som ccr9 antagonister |
| WO2015002994A2 (en) * | 2013-07-02 | 2015-01-08 | Millennium Pharmaceuticals, Inc. | Heteroaryl compounds useful as inhibitors of sumo activating enzyme |
| WO2016126570A1 (en) * | 2015-02-06 | 2016-08-11 | Merck Sharp & Dohme Corp. | Aminoquinazoline compounds as a2a antagonist |
| CA3158951A1 (en) * | 2016-08-15 | 2018-02-22 | Purdue Research Foundation | 4-substituted aminoisoquinoline derivatives |
| MX389798B (es) * | 2017-01-20 | 2025-03-20 | Arcus Biosciences Inc | Azolopirimidina para el tratamiento de trastornos relacionados con el cáncer. |
-
2019
- 2019-07-26 AU AU2019312296A patent/AU2019312296B2/en active Active
- 2019-07-26 KR KR1020217005878A patent/KR102809468B1/ko active Active
- 2019-07-26 EP EP19841391.6A patent/EP3829581B1/en active Active
- 2019-07-26 CN CN201980064256.XA patent/CN112996509B/zh active Active
- 2019-07-26 US US17/263,016 patent/US12064433B2/en active Active
- 2019-07-26 PL PL19841391.6T patent/PL3829581T3/pl unknown
- 2019-07-26 ES ES19841391T patent/ES2982326T3/es active Active
- 2019-07-26 JP JP2021504283A patent/JP7394831B2/ja active Active
- 2019-07-26 WO PCT/US2019/043608 patent/WO2020023846A1/en not_active Ceased
- 2019-07-26 CA CA3107079A patent/CA3107079A1/en active Pending